Intercell: Difference between revisions

Revision as of 19:15, 25 July 2009

Revision as of 20:09, 25 July 2009

Line 31:

}}

'''Intercell AG''' is a biotechnology company based in Vienna which focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Intercell was formed in 1998 as a [[spin-off]] of the [[Research Institute of Molecular Pathology]] of(IMP) thein [[University of Vienna]]. It employs 400 people in Austria, Scotland and the United States.<ref>

{{cite web

|url=http://www.imp.ac.at/about-the-imp/history/

|title=Research Institute of Molecular Pathology (IMP) - About the IMP > History

|publisher=Research Institute of Molecular Pathology

|accessdate=2009-07-25

}}</ref>

It employs 400 people in Austria, Scotland and the United States.

It has been listed on the [[Vienna Stock Exchange]] since [[February 28]], [[2005]]. In 2008, Intercell acquired [[Iomai]], a developer of needle-free vaccination technology, now operated as Intercell USA.<ref>